Myricetin significantly reduced LPS-induced metabolic endotoxemia and systemic inflammation, corrected dyslipidemia and restored liver function in NAFLD rats by regulating the TLR4/NF-κB signaling pathway (Sun et al., 2021). Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.